BofA analyst Michael Cherny downgraded GoodRx (GDRX) to Underperform from Buy with a price target of $4.50, down from $8. The downgrade is driven by uncertainty created by recent announcements from some of the largest stakeholders in the pharmacy ecosystem, and the outlook for GoodRx is more uncertain than at any point during the company’s short life as a public company, the analyst tells investors in a research note. The firm sees downside risk to GoodRx’s earnings, with risks beginning in 2025 if CVS’ (CVS) CostVantage model is broadly adopted.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GDRX:
- Jefferies specialty pharmaceuticals analyst has analyst/industry conference call
- GoodRx management to meet virtually with KeyBanc
- CVS CostVantage to lower value proposition offered by GoodRx, says Wells Fargo
- Hims & Hers weight loss solution ‘will be welcomed,’ says Citi
- GoodRx interim CEO Wagner buys $180K in common stock